Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
Rhea-AI Summary
Propanc Biopharma (NASDAQ: PPCB), a biopharmaceutical company focused on novel cancer treatments, has successfully completed its public offering and uplisting to the Nasdaq Capital Market. The company sold 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 Million.
Trading under the symbol "PPCB" commenced on August 15, 2025, with the offering closing on August 18, 2025. The underwriters, D. Boral Capital LLC and Craft Capital Management LLC, have a 45-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts.
Positive
- Successfully uplisted to Nasdaq Capital Market, providing increased visibility and potential liquidity
- Raised $4 Million in gross proceeds through public offering
- Additional potential capital through 45-day underwriter option for 150,000 shares
Negative
- Dilution of existing shareholders through new share issuance
- Offering-related expenses will reduce net proceeds available to company
News Market Reaction 74 Alerts
On the day this news was published, PPCB gained 69.75%, reflecting a significant positive market reaction. Our momentum scanner triggered 74 alerts that day, indicating high trading interest and price volatility. The stock closed at $6.23 on that trading session. This price movement added approximately $28M to the company's valuation, bringing the market cap to $68M at that time. Trading volume was exceptionally heavy at 7.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that it closed an underwritten public offering of 1,000,000 shares of its common stock, par value
The Company received aggregate gross proceeds of
D. Boral Capital LLC and Craft Capital Management LLC acted as the book running managers for the offering.
Brunson Chandler & Jones PLLC, Salt Lake City, Utah, acted as counsel to the Company, and Sichenzia Ross Ference Carmel LLP, New York, NY, acted as counsel to the underwriters in connection with the offering.
A registration statement on Form S-1 relating to these securities was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2025. The proposed offering was made by means of a prospectus. Electronic copies of the prospectus will also be available on the SEC’s website at http://www.sec.gov or from D Boral Capital LLC, Attention: 590 Madison Avenue 39th Floor, New York, NY 10022, or by email at info@dboralcapital.com, or by telephone at +1(212)-970-5150.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. For more information, please visit www.propanc.com.
The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
FAQ
When did Propanc Biopharma (PPCB) uplist to NASDAQ?
How much money did Propanc Biopharma raise in its public offering?
What was the share price for Propanc Biopharma's public offering?
Who were the underwriters for Propanc Biopharma's NASDAQ uplisting?
What is the underwriter option in Propanc Biopharma's public offering?
